T. Hassanein

Publications335
h-index55
Citations14,785
Highly Influential Citations542
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. McHutchison
  • 730 Publications • 74,501 Citations
  • S. Zeuzem
  • 1,899 Publications • 100,645 Citations
  • E. Lawitz
  • 535 Publications • 34,097 Citations
  • M. Shiffman
  • 582 Publications • 56,207 Citations
  • Publications
  • Influence
Sofosbuvir for previously untreated chronic hepatitis C infection.
TLDR
In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
TLDR
Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination…
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
TLDR
Rates of response to a 12-week interferon-free combination regimen were more than 95% among previously treated patients with HCV genotype 1 infection, including patients with a prior null response.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
TLDR
Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection.
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
TLDR
In 2 phase 3 randomized trials, avatrombopag was superior to placebo in reducing the need for platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD undergoing a scheduled procedure.
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis
TLDR
The use of ECAD may be associated with an earlier and more frequent improvement of HE (grade 3/4) and a full assessment of the role of albumin dialysis awaits the results of additional controlled trials.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2…
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
...
1
2
3
4
5
...